ANDRINI, ELISA
ANDRINI, ELISA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Assegnisti
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
2022 Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
2022 Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G.
An Update on Appendiceal Neuroendocrine Tumors
2023 Andrini E.; Lamberti G.; Alberici L.; Ricci C.; Campana D.
Antibody–drug conjugates for lung cancer in the era of personalized oncology
2021 Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature
2023 Ricco G.; Seminerio R.; Andrini E.; Malvi D.; Gruppioni E.; Altimari A.; Zagnoni S.; Campana D.; Lamberti G.
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities
2022 De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R.
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
2023 Arianna Zappi; irene persano; Linda Galvani; Elena Parlagreco; Elisa Andrini; Davide Campana; Maria Pia Brizzi; Giuseppe Lamberti; ANNA LA SALVIA
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
2022 Ricciuti B.; Mira A.; Andrini E.; Scaparone P.; Michelina S.V.; Pecci F.; Cantini L.; De Giglio A.; Lamberti G.; Ambrogio C.; Metro G.
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies
2022 Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F.
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
2019 Lamberti G.; Andrini E.; Ricciuti B.
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
2022 Andrini E.; Marchese P.V.; De Biase D.; Mosconi C.; Siepe G.; Panzuto F.; Ardizzoni A.; Campana D.; Lamberti G.
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis
2022 Lamberti G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Marchese P.V.; Ricco G.; Casadei R.; Campana D.
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading?
2021 Ricco G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Casadei R.; Campana D.; Lamberti G.
Non-small-cell lung cancer: how to manage RET-positive disease
2022 Andrini E.; Mosca M.; Galvani L.; Sperandi F.; Ricciuti B.; Metro G.; Lamberti G.
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm
2023 Lamberti, Giuseppe; Andrini, Elisa; Ricci, Claudio; Campana, Davide
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023 Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
2022 Cortellini A.; Ricciuti B.; Vaz V.R.; Soldato D.; Alessi J.V.; Dall'olio F.G.; Banna G.L.; Muthuramalingam S.; Chan S.; Majem M.; Piedra A.; Lamberti G.; Andrini E.; Addeo A.; Friedlaender A.; Facchinetti F.; Gorria T.; Mezquita L.; Hoton D.; Valerie L.; Nana F.A.; Artingstall J.; Comins C.; Di Maio M.; Caglio A.; Cave J.; McKenzie H.; Newsom-Davis T.; Evans J.S.; Tiseo M.; D'Alessio A.; Fulgenzi C.A.M.; Besse B.; Awad M.M.; Pinato D.J.
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale | Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Fo...llador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease | Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
| An Update on Appendiceal Neuroendocrine Tumors | Andrini E.; Lamberti G.; Alberici L.; Ricci C.; Campana D. | 2023-01-01 | CURRENT TREATMENT OPTIONS IN ONCOLOGY | - | 1.01 Articolo in rivista | Andrini_2023.pdf |
| Antibody–drug conjugates for lung cancer in the era of personalized oncology | Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R....; Pirro M. | 2021-01-01 | SEMINARS IN CANCER BIOLOGY | - | 1.01 Articolo in rivista | - |
| Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bone targeting agents in patients with metastatic prostate cancer: State of the art | Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucc...i C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2021 [Bone Mets].pdf |
| BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature | Ricco G.; Seminerio R.; Andrini E.; Malvi D.; Gruppioni E.; Altimari A.; Zagnoni S.; Campana D.; ...Lamberti G. | 2023-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities | De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review | Arianna Zappi; irene persano; Linda Galvani; Elena Parlagreco; Elisa Andrini; Davide Campana; Mar...ia Pia Brizzi; Giuseppe Lamberti; ANNA LA SALVIA | 2023-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | jcm-12-00717.pdf |
| How to manage KRAS G12C-mutated advanced non-small-cell lung cancer | Ricciuti B.; Mira A.; Andrini E.; Scaparone P.; Michelina S.V.; Pecci F.; Cantini L.; De Giglio A....; Lamberti G.; Ambrogio C.; Metro G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
| Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies | Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer | Lamberti G.; Andrini E.; Ricciuti B. | 2019-01-01 | JOURNAL OF THORACIC DISEASE | - | 1.01 Articolo in rivista | - |
| Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges | Andrini E.; Marchese P.V.; De Biase D.; Mosconi C.; Siepe G.; Panzuto F.; Ardizzoni A.; Campana D....; Lamberti G. | 2022-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | jcm-11-01461.pdf |
| Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis | Lamberti G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Marchese P.V.; Ricco G.; C...asadei R.; Campana D. | 2022-01-01 | CANCER MEDICINE | - | 1.01 Articolo in rivista | Lamberti_Cancer Medicine_2022.pdf; Downloads.zip |
| Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? | Ricco G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Casadei R.; Campana D.; Lambe...rti G. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-22-10629-v2.pdf |
| Non-small-cell lung cancer: how to manage RET-positive disease | Andrini E.; Mosca M.; Galvani L.; Sperandi F.; Ricciuti B.; Metro G.; Lamberti G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
| Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm | Lamberti, Giuseppe; Andrini, Elisa; Ricci, Claudio; Campana, Davide | 2023-01-01 | THE LANCET ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Peripheral nervous system adverse events associated with immune checkpoint inhibitors | Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lambert...i G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M. | 2023-01-01 | JOURNAL OF NEUROLOGY | - | 1.01 Articolo in rivista | Rossi_JN_2023.pdf |
| Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations | Cortellini A.; Ricciuti B.; Vaz V.R.; Soldato D.; Alessi J.V.; Dall'olio F.G.; Banna G.L.; Muthur...amalingam S.; Chan S.; Majem M.; Piedra A.; Lamberti G.; Andrini E.; Addeo A.; Friedlaender A.; Facchinetti F.; Gorria T.; Mezquita L.; Hoton D.; Valerie L.; Nana F.A.; Artingstall J.; Comins C.; Di Maio M.; Caglio A.; Cave J.; McKenzie H.; Newsom-Davis T.; Evans J.S.; Tiseo M.; D'Alessio A.; Fulgenzi C.A.M.; Besse B.; Awad M.M.; Pinato D.J. | 2022-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | Cortellini et al, Journal for ImmunoTherapy of Cancer 2022.pdf; jitc-2021-004374supp001_data_supplement.pdf |
| Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti... G.; Campana D. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Vescica_SEER.pdf; curroncol-29-00461-s001.zip |